Delivery Order SPE2DB24D1201-SPE2DB25FJDEQ
- Not listed
- The Defense Logistics Agency awarded a $7,245.84 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 2, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, valued at $4,584.29. This is a firm fixed-price delivery order with an ultimate completion date of August 19, 2025, issued under a competitive procurement with no set-aside designation. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, valued at $2,225.76. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order with an ultimate completion date of June 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and is a major pharmaceutical distributor critical to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vemlidy 25 mg tablets (30-count units) with a ceiling value of $7,213.88. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The vendor, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $22,165.99, with an ultimate completion date of June 20, 2025. The contract utilizes no set-aside designation and represents a competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at...
- The Defense Logistics Agency awarded a delivery order valued at $2,873.72 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-unit package) on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime contract...
- The Defense Logistics Agency awarded a delivery order valued at $5,080.98 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on August 27, 2025, with completion scheduled for August 28, 2025. This non-set-aside, firm fixed-price delivery order represents a pharmaceutical procurement supporting federal medical supply needs. The award was issued to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $1,136.54 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). The contract is structured as a firm fixed price delivery order with an ultimate completion date of October 17, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,770.92 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count unit of use packaging). The contract was competitively awarded without set-aside provisions and is classified as a firm fixed price delivery order, with an ultimate completion date of September 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $81,684.20 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on September 24, 2025, with an ultimate completion date of September 25, 2025. This is a firm fixed price, non-set-aside delivery order executed under a competitive procurement process. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDEQDelivery Order
The Defense Logistics Agency awarded a $2,871.10 delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of June 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp continues to compete for renewals under the DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative, which anticipates multiple regional awards among several contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 6/25/25 |